Showing 2141-2150 of 2314 results for "".
- Oxurion Reports Positive Topline Data From Phase 1 Study of THR-687 for Treatment of DMEhttps://modernod.com/news/oxurion-nv-reports-positive-topline-data-from-phase-1-study-evaluating-thr-687-for-treatment-of-dme/2477208/Oxurion has reported positive topline data from a phase 1 study with THR-687, a novel, potent, pan-RGD integrin antagonist for the treatment of diabetic macular edema (DME). The phase 1, open-label, multicenter, single dose escalation study evaluated the safety of a single intravitreal inj
- New Analysis Expands on Link Between Pharma Payments, Prescribinghttps://modernod.com/news/new-analysis-expands-on-link-between-pharma-payments-prescribing/2477201/Doctors who receive money from drugmakers related to a specific drug prescribe that drug more heavily than doctors without such financial ties, a new ProPublica analysis found. The pattern is consistent for almost all of the most widely pr
- AOA: Changes on the Horizon for Evaluation and Management Serviceshttps://modernod.com/news/aoa-changes-on-the-horizon-for-evaluation-and-management-services/2477202/There has been a lot of information disseminated by various individuals and organizations regarding upcoming changes to coding and reimbursement for evaluation and management services (E/M services). Given the importance of E/M services in patient care, it’s critical that all doctors of opt
- Occupational Radiation Exposure Tied to Higher Cataract Riskhttps://modernod.com/news/occupational-radiation-exposure-tied-to-higher-cataract-risk/2477191/Higher cumulative occupational exposure to low-dose radiation is associated with excess additive risk (EAR) of developing cataract, according to a new study in a large prospective cohort of U.S. radiation technologists, Reuters reported. <
- Allergan Foundation Giving Reaches $95 Million Since Inceptionhttps://modernod.com/news/allergan-foundation-giving-reaches-95-million-since-inception/2477188/Allergan announced that The Allergan Foundation has awarded a total of $10 million in charitable grants in 2019. The grants were donated to more than 400 organizations in 32 states as part of The Allergan Foundation’s commitment to providing a lasting and posit
- Nicox’s NCX 4251 Meets Primary Endpoint in Phase 2 Blepharitis Trial and Shows Promising Efficacy in Dry Eye Diseasehttps://modernod.com/news/nicoxs-ncx-4251-meets-primary-endpoint-in-phase-2-blepharitis-trial-and-shows-promising-efficacy-in-dry-eye-disease/2477187/Nicox SA announced that NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals, has met the primary objective of its U.S. multicenter, dose escalating, first-in-human, phase 2 clinical trial (referred to as ‘Danube’) evaluating the safety and tolerability of NCX 4
- The American Optometric Association Urges Employers to Pledge to Make 2020 the Year of the Eye Examhttps://modernod.com/news/the-american-optometric-association-urges-employers-to-pledge-to-make-2020-the-year-of-the-eye-exam/2477180/As part of the American Optometric Association’s (AOA) #2020EyeExam initiative, the organization and doctors of optometry nationwide are calling upon visionary companies across the country to join the 2020 Employer Pledge program–affirming the importance of caring for the overall health and
- Blue Light Glasses: Helpful or Just Hype?https://modernod.com/news/blue-light-glasses-helpful-or-just-hype/2477179/Erin Lynn Sattler started worrying when her vision became blurry while using the computer, but her eye doctor said her eyes were fine. Then she got a new computer at work, with a much brighter screen, and her eyes and head started hurting. She’d heard of blue light glasses and did some
- FDA Advisory Committee Votes Unanimously to Support the Use of Teprotumumab for the Treatment of Thyroid Eye Disease (TED)https://modernod.com/news/fda-advisory-committee-votes-unanimously-to-support-the-use-of-teprotumumab-for-the-treatment-of-thyroid-eye-disease-ted/2477171/Horizon Therapeutics announced that the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) of the FDA voted unanimously that the potential benefits of teprotumumab, a fully human monoclonal antibody (mAb), outweigh the potential risks for the treatment of Thyroid Eye Disease (TED).
- Eyesight Philanthropist James Chen Awarded Honorary Degree by University of Bathhttps://modernod.com/news/eyesight-philanthropist-james-chen-awarded-honorary-degree-by-university-of-bath/2477169/James Chen, a philanthropist committed to solving global problems associated with vision and eye care, has been awarded an honorary degree from the University of Bath, UK. He received his honorary LLD (Doctor of Laws) degree at the Assembly Rooms, Bath, on Tuesday 10 December (12:15 pm). I